Monday, 11 March 2019

Colposcopy Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Scenario
The Global Colposcopy Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.
A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.
For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.
Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.
Company Profiles            
  • Carl Zeiss
  • Olympus Corporation
  • Danaher Corporation
  • Philips Healthcare
  • CooperSurgical
  • McKesson Corporation
  • DYSIS Medical
  • Atmos
  • Alliton
  • Seliga Microscopes
  • Karl Kaps
  • Bovie Medical
Segmentation
The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.
On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.
On the basis of instrument portability, the market is classified into portable, fixed, and handheld.
On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.
On the basis of magnification type, the market is classified into fixed magnification and variable magnification
On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.
The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 
The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.
The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.
Regional Market Summary
 The Americas is likely to dominate the global colposcopy market owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.
Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  
Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.
The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora, Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 8 March 2019

Transgenic Animals Market size and Key Trends in terms of volume and value 2018

Market Scenario

Transgenic animals carry a foreign gene deliberately inserted into its genome.  The insertion of the foreign DNA into the host body is carried out by the application of recombinant DNA technology. The transmission of the foreign gene is facilitated through the germ line so that every cell of the targeted animal contains the same modified genetic material. In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth. According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others. On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others. On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
Regional Analysis
The Americas dominate the transgenic animals market owing to increasing adoption of new technologies and huge patient population for diabetes and cardiovascular diseases. Additionally, rising healthcare expenditure, followed by the presence of developed economies and healthcare sector within the region fuels the market growth.
The transgenic animals market in Europe is the second largest. Rising research and development in the healthcare sector, huge patient population, and growing biotechnology sector are the major drivers for the market growth within the region. The U.K is the fourth-largest contributor to biotechnology research and development worldwide.
Asia Pacific region is the fastest growing market. Increasing awareness for transgenic animals and rising healthcare expenditures are the major drivers for the market growth within the region during the forecast period. Moreover, the presence of the developing economies like India and China which have a developing biotechnology sector within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian biotech industry holds about 2% share of the global biotech industry. The biotechnology industry in India comprises of about 800 companies and is valued to be about USD 11.6 billion in 2017.
The Middle East & Africa has the least share in the transgenic animals market. The presence of poor economies and stringent government policies, especially in the African region restrains the market growth within the region. Majority of the market in the Middle East & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the developed economies like Saudi Arabia, Kuwait, and Qatar within the region.
Key players for transgenic animals market
Cyagen Biosciences, Charles River, Creative-Biolabs, TRANS GENIC INC.., Ltd., Sutter Instrument Company, Bio-Rad Laboratories, Inc., Spinco Biotech Pvt Ltd., Abbott, Thermo Fisher Scientific Inc., Sigma-Aldrich Co., Accumold, and others are some of the major players for transgenic animals market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Anaplasmosis Treatment Market size and Key Trends in terms of volume and value 2018

Market Scenario

Anaplasmosis is a bacterial infection that spreads from animals to humans. More rarely, the bacteria that cause anaplasmosis can spread through direct contact with infected animals. The infection can be treated successfully with antibiotics. According to the Centers for Disease Control and Prevention (CDC), the global burden of human anaplasmosis treatment remains high as the organism causes more than 10,000 infections per year worldwide. Usually, anaplasmosis is more common in males than in females and are generally not occurring in infants.
The frequency of reported cases of anaplasmosis is highest among people over 40 years of age. A compromised immune system such as patients undergoing cancer treatments, advanced human immunodeficiency virus infection, prior organ transplants may increase the risk of the severe outcome. Individuals working or spending time in known tick habitats such as the zoo, animal rearing, and farms may be at increased risk for infection.
Although anaplasmosis infections can occur during any time of the year, the majority of cases reported to the CDC have an illness onset during the summer months and peaks in the months of June and July. This period is the season for the proliferation of nymphal black-legged ticks that bite humans and may transmit the pathogen.
The global market for anaplasmosis treatment is expected to grow at a CAGR of approximately 6.3% during the forecast period 2017-2023.
Segmentation
The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.
On the basis of the species, the market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis, the market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application, the market is segmented into humans, pets, livestock, wildlife, and others 
On the basis of the treatment, the market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, and others.
Key Players
Some of key the players in the global anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany)  Novopharm (Canada), and others.
Regional Analysis
The global anaplasmosis treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East, and Africa.
The American anaplasmosis treatment is the largest market across the globe owing to the high investment in various private and government-funded research, and increased spending on pharmaceutical industry. This condition is commonly reported from the upper midwestern and northeastern United States. the black-legged tick (Ixodes scapularis) is responsible for transmission of A. phagocytophilum in the upper Midwest and northeastern U.S. These tick species also transmit the agents of Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover, the human co-infections with these organisms have occasionally been reported. Anaplasmosis treatment is now being controlled in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock.
European market is projected to hold the second largest share of the global anaplasmosis treatment market as due to the eradication of these disease from Europe. Although some clinical cases of human granulocytic anaplasmosis have been reported in Europe, mostly from Slovenia, Sweden, and Poland, most cases have occurred in the United States. According to the U.S. National Library of Medicine, the prevalence of Ixodes ricinus ticks in Europe is 3% which is as higher than the United States. The average prevalence rate of A. phagocytophilum infection among humans in Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle Eastern region are expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the healthcare sector.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Refsum Disease Market Anticipated To Witness Noteworthy Growth in the Coming Years

Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Intended Audience
  • Pharmaceutical Companies
  • Hospitals & Clinics
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Regional Analysis
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the global refsum disease market are Fresenius Kabi, B. Braun Medical Inc., Medline Industries, Inc., Illumina, Inc., Igenomix, Ceuta Healthcare Limited, Cochlear Ltd., Cook, Sonova, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd., Agilent Technologies, Bio-Rad Laboratories, Inc., Sequenom, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Europe Blood Glucose Monitoring Market Pipeline Review, 2018- Identify Key Business Opportunities

One of the main objectives of diabetes treatment is to keep blood glucose level within a specified target range. Blood glucose monitoring is a process, which helps to identify the blood glucose level and notify if glucose level of blood is exceeding the limit. Thus, it helps to understand the food intake, exercise, insulin, and blood glucose level. The blood glucose monitoring devices provide useful information to manage diabetes. It helps to track the progress of treatment goal as well as monitor the effect of diabetes meditation on blood sugar level and understand the effect of illness and stress on the blood sugar level.
The blood glucose monitoring devices market is growing rapidly owing to the increasing prevalence of diabetes, innovative technology for monitoring and diagnosis of diabetes, early detection of diabetes, and increasing demand for continuous glucose monitoring devices.
Various blood glucose monitoring devices are available in the Europe and the Middle East and African market, which is referred as blood glucose meter. These device help to identify the blood glucose level at home, clinics, hospitals, etc. Furthermore, they are designed to apply to the different type of diabetes such as Type 1 and Type 2.
Blood Glucose monitoring devices market is expected to grow at a CAGR of 6% during the forecast period 2017-2023. Increasing diabetic patient in the Europe has increased the blood glucose monitoring devices market. Different types of glucose monitoring devices are available in the market such as blood glucose meter, continuous glucose monitoring system, Lancets, glucose monitoring strips, and others. Self-monitoring devices are the oldest method for monitoring blood glucose level and are widely used in home, hospital, and clinics.
EMEA blood glucose monitoring market is expected to reach USD 559 million by 2023 at a CAGR of approximately 6% during the forecast period 2017-2023.
Segmentations
The Europe and the Middle East and Africa, blood glucose monitoring devices market is segmented on the basis of product type, application, and end user
On the basis of the product type, it is segmented into invasive glucose monitoring devices, continuous glucose monitoring devices (CGM), flash glucose monitoring devices, and others.
On the basis of the application, it is segmented into type 1 diabetes, type 2 diabetes, and others.
On the basis of the end user, it is segmented into diagnostic centers, hospitals, clinics, research centers, and home care diagnostics.
Regional Analysis
On the regional basis, Europe, Middle East, and Africa blood glucose monitoring market is segmented into two major regions Europe and the Middle East and Africa.
Europe blood glucose monitoring devices market is showing swift growth owing to the increasing diabetic and obese population, unhealthy food, lack of exercise, and many another factor. Europe is leading the market growth with 60% of market share of EMEA market. According to the WHO, in 2016, around 60 million people had diabetes, and its prevalence is increasing in all age groups in Europe.
The Middle East and Africa account for the least share of market owing to poor political conditions in Africa and limited availability of funds and availability of medical facilities but, sound growth is expected over the review period. The Middle East holds the major share of the Middle East & African market due to the presence of well-developed countries like Kuwait, Qatar, Oman and South Arabia. Whereas, African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.
Key Players
Some of the key players in this market are Abbott Laboratories (US), Arkay Inc. (Japan), Bayer Healthcare AG, (Germany), F.Hoffmann-La Roche (Switzerland), LifeScan, Johnson & Johnson (U.S.), Medtronic plc., Nipro Diagnostics Inc., and Terumo Medical Corporation. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Encephalomyelitis Market size and Key Trends in terms of volume and value 2018

Encephalomyelitis is the condition of inflammation in the brain and spinal cord. The disease is caused by a number of factors including viral infection, bacteria and other. During last few years, the number of patients suffering from this disease is increasing due to which this disease has gained a considerable attention. According to the World Health Organization (WHO), 4.3 million people across the globe are affected by encephalomyelitis. The initial phase of disease is characterized by symptoms such as headache, fever, confusion, which in severe condition can led to hallucinations, trouble in speaking, and memory loss. A number of different types of drugs and vaccines are available in the market for the treatment. The patients suffering from autoimmune diseases & AIDS are the most commonly affected by the disease due to weak immune system. The global encephalomyelitis market is majorly driven by the increasing prevalence of encephalomyelitis and rising number of patients suffering from autoimmune diseases & AIDS.  According to the American Autoimmune Related Diseases Association, in 2014, approximately 50 million people in the U.S. are suffering from autoimmune diseases. Additionally, during last decade, the number of patient suffering from AIDS in Asia Pacific region has elevated. Moreover, increasing geriatric population, government support and rapid developments in technology have fuelled the growth of the market. On the other hand, high cost of the treatment and unavailability of precise treatment may restrain the growth of the market.
The global encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 
Segmentations
The global encephalomyelitis market is segmented on the basis of types, treatment and end users.
On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.
On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.
On the basis of end users, the market is segmented into hospital, clinics and others.
Regional Analysis
The Americas dominate the global encephalomyelitis market owing to the increasing prevalence of patients with encephalomyelitis, and autoimmune diseases. Due to rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better drugs. Additionally, well developed technology, high healthcare expenditure, and strong government support for research & development have fuelled the growth of the market in this region.
Europe commands the second largest market for encephalomyelitis which is followed by Asia Pacific. Availability of funds, increasing need for better treatment options and strong government support drive the growth of the market in Europe. Germany, France & U.K holds the major share in the Europe market.
Asia Pacific is the fastest growing encephalomyelitis market owing to the increasing number of patients suffering from autoimmune diseases and AIDS. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market.
On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa. The Middle East region holds the major share in the market owing to well developed technology, and high healthcare expenditure. On the other hand, Africa region shows the fastest growth due to availability of opportunities for the market growth.
Key Players
Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Asia-Pacific Medical Suction Device Market size and Key Trends in terms of volume and value 2018

The medical suction device is basically fitted into hospital for the many medical reasons. A medical suction machine is device used for the respiratory conditions. The respiratory conditions like generally results into secretion of mucous, serum that has to be removed for the body. The device is used to remove serum or mucous when the patient is not able to secrete it out from the body. Also the suction machines are used for several other reasons for example, while operative procedures, delivery of baby. The suction machine utilizes a long catheter to vacuum out the blocking secretions. The secreted material is collected into a jar and then emptied after the process is done. The suction machine work on the power/electric supply or on the battery power. The power required for the machine is 110volts. Batteries of this volts are also available so that the patients can use the device when there is no power supply. The cleaning and replacement of the parts of the machine is very necessary as the machine is used for the patient. So as to maintain the cleanliness the suction machines are cleaned after every use. The cleaning of the machine parts are easy. The machine also has a bacterial filters that are also replaceable and can be replaced very month.
The Asia-Pacific market of Medical Suction Device is growing because of the rising prevalence of diabetes which requires the insulin suction devices, whereas the increasing pollution in the countries are creating the demand for respiratory suction devices. The Asia-Pacific market of Medical Suction Device s is expected to grow with a CAGR of 7% during the forecasted period 2017-2023.
Key Players for Medical Suction Device Market:
Some of the major players in this market are: De Vilbiss Healthcare, Fluke Biomedical, Yang Zhou Huike Electronic, Allied Healthcare Products. Inc, Olympus Corporation, Gemmy Industrial Corp., Ohio Medical, ATMOS Medizin Tchnik, INTEGRA biosciences, Medicop Inc. and others
Segments:
Asia-Pacific Medical Suction Device market has been segmented on the basis of types which comprises of types, usage and suctions parts. On the basis of types there are two major types movable and electrical suction device. On the basis of the usage airway suctioning, gastrointestinal decompression, pleural suctioning, operative suctioning and others. On the basis of the suction parts vacuum pumps, bacterial filter, vacuum gauge, moisture or debris trap, suction catheter and others.
Regional Analysis of Medical Suction Device Market:
Asia-Pacific region is divided into two major regions, Asia and Pacific. Further Asia is divided into the Countries like Japan, China, India, Republic of Korea, Rest of Asia. The Asia-Pacific market for Medical Suction Device is estimated to grow at a rapid pace during the forecasted period 2017-2023. This is due to increasing number in the technology adoption for the medical devices and the homecare devices. The large number of the respiratory suction devices are in great demand. Countries like China and India have increasing number of chronic respiratory diseases. The increasing number of diabetes in India have a great demand for the insulin suction devices.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)